Status:
COMPLETED
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
Lead Sponsor:
Pfizer
Conditions:
Dermatitis, Contact
Eligibility:
All Genders
Brief Summary
This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life eff...
Eligibility Criteria
Inclusion
- To be eligible for enrollment in this study, patients must be prescribed oral Medrol tablets (4mg and 16 mg) for contact dermatitis as per the locally approved prescribing information
- Medrol tablets, will be prescribed to the patient by the physician according to his/her usual practice. The decision to prescribe Medrol tablet will necessarily precede and will be independent of the decision to enroll patient into the study
- Only those patients, who are ready to sign an informed consent, will be included in the study
- Subject can be contacted through telephone
Exclusion
- Patients who have any other dermatological or systemic condition that may interfere or confound with the study outcome measurements
- Patients taking any oral steroid preparation or immunomodulators or have taken any such oral medication during last 15 days before enrollment. NSAIDs (Non Steroidal Anti-Inflammatory Agents) are excluded from the list
- Any contraindication to Medrol tablet use. Contraindications of Medrol use are systemic fungal infections and known hypersensitivity to components
- Participation in other studies within last 1 month before the current study begins and/or during study participation
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00929981
Start Date
September 1 2009
End Date
September 1 2010
Last Update
January 2 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bangalore, Karnataka, India, 560 038
2
Pfizer Investigational Site
Mumbai, Maharashtra, India, 400 058
3
Pfizer Investigational Site
Mumbai, Maharashtra, India, 421 201
4
Pfizer Investigational Site
Ludhiana, Punjab, India, 141001